The original vision of “personalized medicine” focused on tailoring medications to the biology of the individual patient — treating them with the right drug at the right time. That view has since evolved beyond therapy selection to increasingly encompass aspects of drug discovery, planning and delivery of care, and patient engagement. This new approach, now...
We were pleased to participate in a “State of the Industry” panel on immuno-oncology at the 2015 BIO Investor Forum in October. The lively discussion included other participants from across the industry and investing world, including the licensing office of Merck & Co. and Baxter’s corporate venture arm, Baxalta, as well as small biotech company...